Table 3.

Univariate analysis for possible risk factors associated with time to LTP, DFS, OS (months)

Risk factors	TLTP (mean ± SD)	P	DFS (mean ± SD)	P	Overall survival (mean ± SD)	P
Age
>65	29.13 ± 3.59	0.204	11.39 ± 1.57	0.676	31.86 ± 2.76	0.419
<65	30.22 ± 3.26		12.72 ± 2.51		30.44 ± 2.69
Gender
M	26.65 ± 2.92	0.334	12.92 ± 1.83	0.669	31.12 ± 2.64	0.896
F	35.93 ± 3.97		11.68 ± 2.1		34.012 ± 3.08
Subcapsular
Yes	28.98 ± 3.28	0.429	10.46 ± 1.48	0.142	32.35 ± 2.64	0.917
No	35.32 ± 3.93		14.54 ± 2.34		33.46 ± 3.16
Type of tumor
HCC	34.61 ± 2.796	0.09	17.75 ± 4.10	0.09	31.86 ± 4.59	0.955
Metastasis	30.27 ± 3.066		10.3 ± 1.4		33.58 ± 2.39
Differentiation of primary tumor
Good	No events	0.07	No events	0.01	11.11 (1 event)	0.465
Moderate	28.33 ± 4.08		10.3 ± 1.29		33.73 ± 3.03
Poor	12.11 ± 3.28		7.38 ± 1.42		19.8 ± 6.73
HCC	34.13 ± 2.99		17.75 ± 4.1		31.86 ± 4.59
Needle
Radiotherapeutics	29.54 ± 4.35	0.46	13.68 ± 2.52	0.876	32.1 ± 3.46	0.344
RITA	36.23 ± 6.45		11.88 ± 3.38		39.69 ± 5.09
Radionics	31.55 ± 3.92		12.07 ± 2.06		30.49 ± 3.03
Laser	26.66 ± 6.23		11.33 ± 3.91		30.96 ± 5.98
Tumor size
>4 cm	15.25 ± 3.89	0.001	10.98 ± 3.14	0.663	27.94 ± 4.57	0.203
<4 cm	36.22 ± 2.96		12.1 ± 1.59		34.49 ± 2.46
Approach
Open	34.91 ± 3.14	0.219	13.52 ± 1.71	0.228	34.34 ± 2.69	0.443
Percutaneous	22.71 ± 3.69		10.5 ± 2.35		27.34 ± 2.47
Pringle
Yes	28.48 ± 5.65	0.727	10.28 ± 3.26	0.382	31.65 ± 4.81	0.818
No	32.33 ± 2.91		12.94 ± 1.57		33.54 ± 2.34
Track ablation
Yes	32.99 ± 3.39	0.899	10.96 ± 1.76	0.458	33.3 ± 2.75	0.876
No	30.28 ± 3.94		13.75 ± 2.11		32.95 ± 3.06
Cells macroscopically visible
Yes	32.97 ± 3.87	0.907	13.31 ± 2.04	0.543	35.18 ± 3.08	0.404
No	31.49 ± 3.45		11.87 ± 1.89		30.79 ± 2.71
Vital cells
Yes	21.19 ± 3.27	0.038	14.01 ± 2.38	0.323	34.75 ± 3.41	0.538
No	36.34 ± 3.09		11.91 ± 1.71		32.45 ± 2.57

Time to LTP, DFS, and OS are calculated with the Kaplan–Meier method